Business
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to accelerate the development of Akari’s novel PH1 payload. “This strategic partnership with WuXi XDC re
About this update from Wuxi Xdc Cayman, Inc.
[{"type":"image","alt":"Akari Therapeutics Plc","displaySize":"","headline":null,"caption":"Akari Therapeutics Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":260,"url":"https://media.zenfs.com/en/globenewswire.com/34bd8bbf77b3fcbc303935b4ef907d4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aDG0YUAPvKFMGmAIA6257Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM2NA--/https://media.zenfs.com/en/globenewswire.com/34bd8bbf77b3fcbc303935b4ef907d4e","width":300,"height":260}},"lazy":false},{"type":"text","content":"Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026","length":73,"tagName":"p"},{"type":"text","content":"TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to accelerate the development of Akari’s novel PH1 payload.","length":387,"tagName":"p"},{"type":"text","content":"“This strategic partnership with WuXi XDC represents a major milestone for Akari and a powerful validation of our novel PH1 payload technology,” said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. “WuXi XDC is widely recognized as a global leader in ADC innovation, and with this partnership, we believe Akari can rapidly advance and further validate our PH1 payload on AKTX-101 in future clinical studies.”","length":442,"tagName":"p"},{"type":"text","content":"WuXi XDC’s CEO, Jimmy Li, Ph.D., added, “We are pleased to work with Akari to advance the novel PH1 payload into more advanced studies. WuXi XDC has a proven record of advancing novel ADC payloads and strives to remain at the forefront of ADC innovation. We believe we are the trusted and best partner to help Akari advance this first-in-kind RNA splicing modulating ADC payload for its use in its lead program, as well as other future ADC molecules. There is a strong need for ADC payload innovation to improve on current therapies, and WuXi XDC wants to be at the forefront working with partners like Akari to bring novel ADCs to cancer patients.”","length":649,"tagName":"p"},{"type":"text","content":"Akari’s lead program AKTX-101 is initially targeting metastatic urot...